A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

Conditions

• Ovarian Cancer

Interventions

• DRUG: Investigator's choice of Chemotherapy
• DRUG: Azenosertib

Sponsor

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Collaborators

• [object Object]
• [object Object]